Refanezumab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Humanized (from mouse) |
| Target | myelin-associated glycoprotein |
| Clinical data | |
| Other names | GSK249320 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Formula | C6608H10156N1732O2064S44 |
| Molar mass | 148298.64 g·mol−1 |
Refanezumab (GSK249320) is a monoclonal antibody designed for the recovery of motor function after stroke.[1][2]
This drug was developed by GlaxoSmithKline.
References
- ↑ "Refanezumab" (PDF). Statement On A Nonproprietary Name Adopted By The USAN Council. American Medical Association..
- ↑ Cramer SC, Enney LA, Russell CK, Simeoni M, Thompson TR (March 2017). "Proof-of-Concept Randomized Trial of the Monoclonal Antibody GSK249320 Versus Placebo in Stroke Patients". Stroke. 48 (3): 692–698. doi:10.1161/STROKEAHA.116.014517. PMC 5325241. PMID 28228578.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.